Aphria Inc (APHA) Receives a Sell from CIBC

By Austin Angelo

In a report released yesterday, John Zamparo from CIBC maintained a Sell rating on Aphria Inc (APHAResearch Report), with a price target of $6.50. The company’s shares closed last Monday at $5.43, close to its 52-week low of $3.75.

Zamparo has an average return of 30.6% when recommending Aphria Inc.

According to TipRanks.com, Zamparo is ranked #5236 out of 5546 analysts.

Currently, the analyst consensus on Aphria Inc is a Moderate Buy with an average price target of $7.96.

See today’s analyst top recommended stocks >>

Based on Aphria Inc’s latest earnings release for the quarter ending May 31, the company reported a quarterly net profit of $11.76 million. In comparison, last year the company had a net profit of $16.33 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aphria, Inc. engages in the production and supply of medical cannabis. It operates through the following segments: Cannabis Operations, Distribution Operations, and Business Under Development. The Cannabis Operations segment produces, distributes, and sells both medical and adult-use cannabis.